EARLY ONSET PREECLAMPSIA

# THE POWER TO KNOW SOONER

PreeclampsiaScreen™ | T1

PerkinElmer® Labs

NTD

# EARLY ONSET PREECLAMPSIA: A CLINICAL DILEMMA

Early onset preeclampsia is defined as preeclampsia resulting in the delivery of the fetus before 34 weeks' gestation. It is estimated to occur in approximately 0.5% of all pregnancies.[1-5] Early onset preeclampsia is less common than the late form of the disorder but contributes more to the morbidity and mortality of pregnant mothers and babies.[1-5]

Possible early intervention options for preeclampsia include increased monitoring, modified activity, bed rest and medications, including aspirin.[5-10] To date, there has been no reliable way to detect early onset preeclampsia, particularly for patients experiencing their first pregnancy. Therefore, there has been no satisfactory method with which to stratify patients at high risk of early onset preeclampsia from those at lower risk. Until now.

## PreeclampsiaScreen™ | T1. The Power to Know Sooner.

PreeclampsiaScreen™ I T1 is a first-of-its-kind serum screening test that detects three biochemical markers in the mother's blood: **PAPP-A** (pregnancy-associated plasma protein-A); **PlGF** (placental growth factor) and **AFP** (alpha fetoprotein). Together, these three biochemical markers can contribute to accurate prediction of risk for early onset preeclampsia.[3,5,10-16]

**MoM in Early Onset Preeclampsia**




*Multiples of the median (MoM) express how far a test result deviates from the norm for an entire population. Shown here, values of various markers associated with early onset preeclampsia fall either above or below the norm.*

PreeclampsiaScreen™ I T1 enables accurate detection of early onset preeclampsia risk, allowing for earlier intervention and management of the pregnancy.

## Earlier Prediction for Earlier Intervention.

Adding Preeclampsia**Screen**™ I T1 to your current screening protocol can enhance your ability to identify at-risk patients sooner so that more may be done to prevent or delay onset.

### THE BENEFITS:

- **Highest sensitivity in a biochemical screen.** Provides a detection rate of 60% at a 5% false positive rate for early onset preeclampsia when combined with patient history and demographics.[17]
- **91% sensitivity when combined with 2 additional biophysical markers.** Detection rate as high as 91% at a 5% false positive rate for early onset preeclampsia when combined with two additional biophysical markers: uterine artery Doppler pulsatility index (UtAD-PI) and mean arterial blood pressure (MAP).[17]
- **Practical.** Helps you identify those patients who may require increased vigilance.
- **Convenient.** Can be ordered at the same gestational age/patient visit as first trimester aneuploidy screening.
- **Timely.** Results can be obtained as early as 10 weeks, 2 days' gestation.

**PreeclampsiaScreen™ I T1 can enhance the detection rate of your current screening protocol.**

**60%**
Biochemistry + History

**77%**
Biochemistry + History + MAP

**91%**
Biochemistry + History + MAP + UtAD-PI

## Widen the Window of Opportunity, for Your Patients at Risk of Early Onset Preeclampsia.

Early detection of early onset preeclampsia allows a valuable window of opportunity for vigilance and intervention.[16] First trimester identification of risk for preeclampsia enables:

- Early identification of asymptomatic high-risk group of patients
- Increased surveillance of high-risk pregnancies
- Wider-ranging intervention possibilities, including increased monitoring, modified activity, bed rest and medications, including aspirin

## Don't wait and wonder. Know and act sooner, with Preeclampsia**Screen**™ I T1.

For more information, contact your PerkinElmer Labs/NTD sales representative or visit/call us at **www.ntdlabs.com/preeclampsia, 1-888-NTD-LABS (683-5227).**

## Increase Your Vigilance, Guide Your Treatment.

Combined with two biophysical markers, Preeclampsia**Screen**™ I T1 can greatly increase your ability to detect patient risk for early onset preeclampsia.

### TEST SPECIFICATIONS FOR EARLY ONSET PREECLAMPSIA, COMBINATIONS OF MARKERS + HISTORY

| | Biochemistry + History | Biochemistry + History + MAP | Biochemistry + History + UtAD-PI | Biochemistry + History + MAP + UtAD-PI |
|---|---|---|---|---|
| **Markers** | PlGF, PAPP-A, AFP | PlGF, PAPP-A, AFP, MAP | PlGF, PAPP-A, AFP, UtAD-PI | PlGF, PAPP-A, AFP, MAP, UtAD-PI |
| **Gestational age (ultrasound dated)** | 10 weeks, 0 days – 13 weeks, 6 days | 11 weeks, 1 day – 13 weeks, 6 days | 11 weeks, 1 day – 13 weeks, 6 days | 11 weeks, 1 day – 13 weeks, 6 days |
| **Detection rate at 5% FPR*** | **60%** | **77%** | **82%** | **91%** |
| **Requirements** | 5 ml maternal serum in SST (red/gray speckled or gold) tube or red top tube | 5 ml maternal serum in SST tube or red top tube, MAP measurement | 5 ml maternal serum in SST tube or red top tube, UtAD-PI measurement | 5 ml maternal serum in SST tube or red top tube, MAP **and** UtAD-PI measurement |

*False positive rates are representative of a general screening population. Rates may vary depending on history. Risk cutoff in each case is 1 in 50.

## About PerkinElmer Labs/NTD

The Preeclampsia**Screen**™ I T1 testing service is offered by PerkinElmer Labs/NTD, a pioneer in screening for aneuploidy and open neural tube defects (ONTDs).

- Known for the highest first trimester detection rates available for biochemical Down syndrome screening[18]
- Long recognized as a leading innovator with more than 30 years' experience in prenatal screening

**Learn more.** For more information, contact your PerkinElmer Labs/NTD sales representative or visit/call us at:

**www.ntdlabs.com/preeclampsia**
**1-888-NTD-LABS (683-5227)**


**References**

1. von Dadelszen P, Magee LA, Roberts JM. Subclassification of pre-eclampsia. Hypertens Pregnancy 2003;22:143-8.
2. Hernández-Díaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ 2009 Jun 18;338:b2255.
3. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009 May;53(5):812-8. Epub 2009 Mar 9.
4. Onwudiwe N, Yu CK, Poon LC, Spiliopoulos I, Nicolaides KH. Prediction of pre-eclampsia by a combination of maternal history, uterine artery Doppler and mean arterial pressure. Ultrasound Obstet Gynecol 2008;32:877-83.
5. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2012. Published online Aug 16, 2012.
6. U.S. National Library of Medicine. Preeclampsia. (Sept. 12, 2011). http://www.nlm.nih.gov/medlineplus/ency/article/000898.htm. Accessed online May 9, 2012.
7. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest J-C, Giguère Y. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116:402-14.
8. Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet 2000 Apr;38(4):305-14.
9. Watson KV, Moldow CF, Ogburn PL, Jacob HS. Magnesium sulfate: rationale for its use in preeclampsia. Proc Natl Acad Sci 1986 Feb;83(4):1075-8.
10. North RA, Ferrier C, Gamble G, Fairley KF, Kincaid-Smith P. Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. Aust N Z J Obstet Gynaecol 1995 Nov;35(4):357-62.
11. Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008;32:732-9.
12. Waller DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB. The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstet Gynecol 1996 Nov;88(5):816-22.
13. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011;31:66-74.
14. Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH. Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia. Ultrasound Obstet Gynecol 2010;35:680-7.
15. Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol 2010;35:662-70.
16. Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH. Hypertensive disorders in pregnancy: combined screening by uterine Doppler, blood pressure and serum PAPP-A at 11-13 weeks. Prenat Diagn 2010;30:216-23.
17. PerkinElmer. Data on file.
18. Perni SC, Predanic M, Kalish RB, Chervenak FA, Chasen ST. Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials. Am J Obstet Gynecol 2006;194(1):127-30.


PerkinElmer® Labs
NTD

Pursuant to applicable federal and/or state laboratory requirements, PerkinElmer Labs/NTD has established and verified the accuracy and precision of its testing services.




NTD-51063-0713 Printed in USA